[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Chest Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":624},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,53,77,104,129,150,181,203,228,258,284,306,338,360,383,403,423,443,467,489,513,536,562,582,605],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100054190","segmentectomy-versus-lobectomy-for-deep-solid-dominant-early-stage-nsclc-100054190",false,"NCT07698990","Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC","Comparison of Segmentectomy and Lobectomy for Deeply Located, Solid-Dominant Early-Stage Non-Small Cell Lung Cancer (\u003C=2 cm): A Multicenter, Open-Label, Phase III, Randomized, Controlled, Non-Inferiority Clinical Trial","SOLID","Inclusion Criteria:\n\n1. Age 18 to 80 years.\n2. Solitary pulmonary nodule with maximum diameter \\\u003C=2 cm confirmed by preoperative thin-slice CT (\\\u003C=1 mm) and 3D reconstruction.\n3. Solid-dominant nodule with consolidation-to-tumor ratio (CTR) \\>0.5, including pure-solid nodules.\n4. Deeply located lesion, defined as the lesion center located in the inner two-thirds of the lung field on axial, coronal, and sagittal MPR images.\n5. Clinically definite suspected primary NSCLC after complete preoperative work-up and MDT discussion, with estimated malignancy probability \\>=95%. Preoperative pathologic confirmation is not mandatory, but preoperative or intraoperative pathology should be obtained when technically safe and feasible.\n6. Complete staging with thin-slice contrast-enhanced chest CT, whole-body PET-CT, brain contrast-enhanced MRI or CT, and serum tumor markers as appropriate; clinical stage IA (cT1a-bN0M0) without regional nodal or distant metastasis.\n7. Cardiopulmonary function sufficient to tolerate both lobectomy and segmentectomy, with FEV1 and DLCO \\>=60% predicted.\n8. Written informed consent, including special disclosure that final pathology may be benign.\n9. Centralized imaging review confirmation by the lead-center technical committee before randomization.\n\nExclusion Criteria:\n\n1. Lesion located in the right middle lobe.\n2. Lesion located in the inner two-thirds but adjacent to the lung apex or base and judged suitable for wedge resection.\n3. Two or more lesions requiring anatomic resection. One secondary lesion requiring only non-anatomic wedge resection is allowed; two main lesions in the same segment are excluded.\n4. Prior ipsilateral lung surgery or another malignancy within 5 years.\n5. Severe cardiovascular or cerebrovascular disease or other comorbidity making lobectomy or conversion to lobectomy intolerable.\n6. Planned basal segmentectomy (S7-10); proper segmentectomy is permitted.","ALL","18 Years","80 Years",{"count":22,"type":23},1200,"ESTIMATED","INTERVENTIONAL",[26],"NA","SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung cancer (NSCLC) measuring \\\u003C=2 cm. Eligible participants will undergo centralized imaging review and will be randomized preoperatively in a 1:1 ratio before induction of anesthesia.\n\nThe primary endpoint is 5-year overall survival. The key supportive secondary endpoint is 5-year recurrence-free survival. The study will enroll 1,200 participants and will use intention-to-treat analysis for the primary endpoint. An independent Data and Safety Monitoring Board and an independent Endpoint Adjudication Committee will oversee safety, surgical quality, data quality, and endpoint adjudication.",[29,30],"Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Cancer",[32,33,34,35,36,37,38,39],"segmentectomy","lobectomy","deep pulmonary nodule","solid-dominant nodule","early-stage NSCLC","non-inferiority trial","overall survival","recurrence-free survival","NOT_YET_RECRUITING","2026-07-07",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":23},"2026-07",{"date":48,"type":23},"2034-07",{"name":50,"class":51},"Shanghai Chest Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100644610","xuan-yin-ning-plus-bevacizumab-for-malignant-pleural-effusion-100644610","NCT07670338","Xuan Yin Ning Plus Bevacizumab for Malignant Pleural Effusion","A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of Xuan Yin Ning Formula Combined With Intrapleural Injection of Bevacizumab for the Treatment of Malignant Pleural Effusion.","XYN-Bev MPE","Inclusion Criteria:\n\n* Patients with advanced non-squamous non-small cell lung cancer who have failed at least first-line systemic therapy;\n* Presence of unilateral pleural effusion confirmed as malignant by pathology or cytology, with at least moderate volume requiring drainage (moderate pleural effusion defined as: supine ultrasound examination showing pleural effusion ≥3 cm, or sitting ultrasound examination showing pleural effusion ≥4 cm,accompanied by clinical symptoms such as chest tightness and dyspnea);\n* Age 18-75 years;\n* ECOG performance status 0-2;\n* Traditional Chinese Medicine (TCM) syndrome differentiation classified as Xuanyin (suspension fluid) with fluid retention in the chest and hypochondrium;\n* Expected survival of at least 3 months;\n* Voluntarily signed informed consent before treatment;\n* No contraindications to chest tube placement for drainage;\n* Adequate major organ function, including:\n\n  1. Complete blood count:\n\n     White blood cell count ≥ 4.0×10⁹\u002FL Absolute neutrophil count ≥ 1.5×10⁹\u002FL Platelet count ≥ 100×10⁹\u002FL Hemoglobin ≥ 90 g\u002FL\n  2. Blood biochemistry:\n\n     Total bilirubin ≤ 1.5×ULN ALT ≤ 2.5×ULN, AST ≤ 2.5×ULN Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula)\n  3. Coagulation function:\n\n     International normalized ratio (INR) ≤ 1.5×ULN Activated partial thromboplastin time (APTT) ≤ 1.5×ULN\n  4. Blood glucose: within normal range, or diabetic patients under treatment with stable blood glucose control;\n* Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug administration, and must use effective contraception (e.g., intrauterine device, contraceptive pills, or condoms) during the study period and for at least 3 months after the last dose. -Male subjects with a partner of childbearing potential must use effective contraception during the study period and for 3 months after the last dose;\n* Good subject compliance, able to follow up for efficacy and adverse events\u002Freactions as required by the protocol.\n\nExclusion Criteria:\n\n* The location of pleural effusion is unsuitable for drainage, or the patient would not benefit from intrapleural drug administration (e.g., severe loculation\u002Fseptation);\n* Other contraindications to indwelling chest tube placement;\n* Pleural effusion with active infection;\n* Prior history of ipsilateral chest tube drainage and intrapleural anti-tumor drug therapy or pleurodesis;\n* Prior history of empyema or chylothorax;\n* Participation in another clinical trial within 4 weeks before signing informed consent;\n* Known allergy to any component of the study drugs;\n* Severe bleeding tendency or active bleeding;\n* Uncontrolled severe hypertension;\n* Recent (within 3 months) thromboembolic events, such as deep vein thrombosis, pulmonary embolism, cerebral infarction, etc.;\n* Prior severe adverse reactions to intravenous bevacizumab, such as severe proteinuria, gastrointestinal perforation, hypertensive crisis, etc.;\n* Severe cardiac, hepatic, or renal insufficiency;\n* Pregnant or breastfeeding women;\n* Subjects with other active infectious diseases in the acute phase;\n* Any other factors that, in the investigator's judgment, may lead to premature termination of the study, such as other serious diseases (including psychiatric disorders) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the subject's safety or compliance.","75 Years",{"count":63,"type":23},308,[26],"The goal of this clinical trial is to determine whether the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage is effective in treating malignant pleural effusion. It will also evaluate the safety of this combination therapy. The main questions it aims to answer include:\n\nDoes the Xuanyin Ning Formula combined with intrapleural injection of bevacizumab via chest tube drainage improve the objective response rate (ORR) of pleural effusion in patients with malignant pleural effusion? Does this combination therapy affect the duration of response (DoR), progression-free survival (PFS), overall survival (OS), degree of dyspnea, quality of life, and Traditional Chinese Medicine (TCM) pattern\u002Fsyndrome evaluation in patients with malignant pleural effusion?\n\nParticipants will:\n\nReceive intrapleural injection of bevacizumab via chest tube drainage, and take either Xuanyin Ning Formula or placebo granules daily for 8 weeks.\n\nUndergo ultrasound assessment of pleural effusion at 2, 4, 8, and 12 weeks after the first intrapleural injection during closed chest drainage, followed by ultrasound assessments every 3 months (±7 days) until pleural effusion progression.",[67],"Malignant Pleural Effusions (Mpe)","2026-06-29",{"date":70,"type":44},"2026-07-01",{"date":72,"type":23},"2026-06-01",{"date":74,"type":23},"2028-09-01",{"name":50,"class":51},7,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":86,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100645241","label-free-femtosecond-laser-imaging-combined-with-the-fast-lung-artificial-intelligence-model-for-rapid-intraoperative-diagnosis-of-lung-surgical-specimens-a-multicentre-prospective-parallel-workflow-non-inferiority-study-100645241","NCT07681245","Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.","Inclusion Criteria:\n\n1. Preoperative imaging suggests a pulmonary nodule, pulmonary space-occupying lesion, or suspected pulmonary tumor lesion.\n2. The participant is scheduled to undergo pulmonary wedge resection, segmentectomy, lobectomy, or other pulmonary surgery.\n3. Fresh lung tissue specimens can be obtained intraoperatively for femtosecond laser imaging.\n4. Intraoperative frozen section diagnosis is planned to assess the nature of the tumor lesion.\n5. Corresponding postoperative paraffin-embedded pathological diagnosis can be obtained.\n6. The participant or the participant's legally authorized representative has signed the written informed consent form.\n\nExclusion Criteria:\n\n1. The intraoperative specimen is insufficient and cannot simultaneously meet the requirements for routine clinical pathological diagnosis and research-related testing.\n2. The specimen shows severe carbonization, necrosis, compression, contamination, or improper preservation, and the investigator determines that effective imaging cannot be completed.\n3. The femtosecond laser imaging specimen cannot be matched with the corresponding lesion assessed by final paraffin pathology.\n4. Final paraffin-embedded pathological diagnosis cannot be obtained.\n5. The participant withdraws informed consent.\n6. Other conditions that, in the opinion of the investigator, make the participant unsuitable for this study.","90 Years",{"count":85,"type":23},294,"30 Days","OBSERVATIONAL","This study aims to evaluate whether femtosecond laser imaging combined with FastLung AI model can provide intraoperative diagnostic performance that is non-inferior to standard frozen section diagnosis for pulmonary nodules or suspected pulmonary tumor lesions. Patients scheduled for lung surgery and requiring intraoperative pathological assessment will be prospectively enrolled. After tumor excision, the fresh tumor specimen will be bisected through the central plane. One half will be used for standard frozen section diagnosis, and the mirrored counterpart will be used for femtosecond laser imaging. Both diagnostic results will be compared with the final paraffin-embedded pathological diagnosis as the reference standard. The results of femtosecond laser imaging will not guide intraoperative clinical decision-making.",[90],"Lung Cancer",[92,93,94],"lung cancer","artificial intelligence","Intraoperative diagnosis","2026-06-26",{"date":97,"type":44},"2026-07-02",{"date":99,"type":23},"2026-06-30",{"date":101,"type":23},"2026-09-30",{"name":50,"class":51},5,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":113,"briefSummary":116,"conditions":117,"keywords":118,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100644350","phase-2-syhx2011-in-combination-with-carboplatin-and-enlonstobart-as-first-line-therapy-for-squamous-non-small-cell-lung-cancer-100644350","NCT07662811","SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","SYHX2011 in Combination With Carboplatin and Enlonstobart Versus Nab-Paclitaxel Plus Carboplatin and Tislelizumab as First-Line Therapy for Squamous Non-Small Cell Lung Cancer: A Multicenter, Open-Label, Phase II\u002FIII Study","Inclusion Criteria:\n\n1. Age: ≥18 years old\n2. Histologically or cytologically confirmed locally advanced or metastatic squamous non-small cell lung cancer (Stage IIIB, IIIC, or IV according to the IASLC 9th Edition TNM Staging System), ineligible for radical surgery and\u002For radical radiotherapy\n3. Confirmed negative for driver genes (including EGFR mutation, ALK fusion, ROS1 fusion, etc.)\n4. Tumor cell PD-L1 expression in tumor tissue ≥1% (TPS ≥1%)\n5. No prior systemic anti-tumor therapy for Stage IIIB\u002FIIIC and IV NSCLC, including chemotherapy, targeted therapy, biological therapy, immunotherapy, immunomodulatory drugs, Chinese herbal medicines or proprietary Chinese medicines, and other investigational drugs for tumor control\n6. ECOG PS score 0\\~1\n7. At least one measurable lesion according to the RECIST 1.1 criteria\n8. Adequate bone marrow and other organ functions:(1)Hematology: No significant signs of hematological disease; absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL, platelet count (PLT) ≥75×10\\^9\u002FL, hemoglobin (Hb) ≥90 g\u002FL at screening. For patients with hematological indicators at the critical value who fail to meet the above criteria, the investigator will determine eligibility based on the patient's physical condition. (2)Coagulation function: International Normalized Ratio (INR) ≤1.5 × upper limit of normal (ULN); activated partial thromboplastin time (APTT) ≤1.5 × ULN. (3)Hepatic and renal function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) both ≤2.5 × ULN; for patients with hepatic metastasis, both AST and ALT ≤5 × ULN. Total bilirubin (TBiL) ≤1.5 × ULN; for patients with known Gilbert's disease: serum total bilirubin level ≤3 × ULN. Serum creatinine (Cr) ≤1.5 × ULN\n9. Expected survival ≥3 months\n10. Able to understand the study details; the patient and\u002For legal guardian voluntarily consents to participate in the study and signs the informed consent form\n\nExclusion Criteria:\n\n1. History of or current with other malignant tumors (excluding non-melanoma skin cancer, in situ breast cancer, in situ cervical cancer, and superficial bladder cancer that have been effectively controlled within the past 5 years)\n2. Active leptomeningeal disease or poorly controlled, untreated brain metastases (excluding patients with brain metastases that are well-controlled with local therapy)\n3. Interstitial lung disease (ILD), drug-induced interstitial pneumonitis, or non-infectious pneumonitis (including radiation pneumonitis, pulmonary fibrosis, acute lung disease requiring steroid therapy), and patients with severe impairment of pulmonary function\n4. Active autoimmune disease or a history of autoimmune disease (e.g., ulcerative colitis, Crohn's disease, etc.). However, participants with the following conditions are eligible for further screening: well-controlled type 1 diabetes mellitus; well-controlled hypothyroidism requiring only hormone replacement therapy; dermatological diseases not requiring systemic therapy (e.g., vitiligo, psoriasis, alopecia); or participants with diseases not expected to relapse in the absence of external triggers\n5. Peripheral neuropathy of Grade ≥2 per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0\n6. Pleural effusion, peritoneal effusion, or pericardial effusion requiring clinical intervention within 2 weeks prior to the first administration of the study drug\n7. History of severe cardiovascular disease within 6 months prior to the first administration of the study drug, including but not limited to:(1)Severe cardiac rhythm or conduction abnormalities (e.g., ventricular arrhythmias requiring clinical intervention, third-degree atrioventricular block, etc.); Fridericia-corrected QT interval (QTcF) \\> 480 ms (Fridericia formula: QTcF=QT\u002FRR\\^0.33, where RR=60\u002Fheart rate);(2)History of myocardial infarction, unstable angina pectoris, angioplasty, or coronary artery bypass graft surgery;(3)Heart failure of New York Heart Association (NYHA) Functional Class Ⅱ or higher; left ventricular ejection fraction (LVEF) \\\u003C 50% as detected during screening\n8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection: Hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (anti-HBc) positive, with HBV DNA copy number ≥ 1×10\\^4 copies\u002FmL (or ≥ 2000 IU\u002FmL); Hepatitis C virus antibody (anti-HCV) positive, with HCV RNA level exceeding the lower limit of quantification (LLOQ) of the applied analytical method\n9. Severe infection occurring within 4 weeks prior to the first study drug administration (including but not limited to bacteremia requiring hospitalization, severe pneumonia, active pulmonary tuberculosis, etc.); active infection requiring systemic antibiotic therapy within 2 weeks prior to the first study drug administration\n10. Lactating or pregnant females; females of childbearing potential with a positive blood pregnancy test within 7 days before study enrollment; all male and female patients of childbearing potential who decline to use highly effective contraceptive methods throughout the study period and for 6 months after the last drug administration\n11. Known hypersensitivity or anaphylaxis to any study drug, or a history of other severe hypersensitivity reactions\n12. History of immunodeficiency (including positive human immunodeficiency virus (HIV) test results, other acquired or congenital immunodeficiency diseases); a history of allogeneic stem cell or organ transplantation; other conditions that the investigator deems unsuitable for study participation (e.g., psychiatric disorders, uncontrolled or poorly controlled hypertension and diabetes mellitus, etc.)",{"count":112,"type":23},396,[114,115],"PHASE2","PHASE3","Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer",[29],[119,120,121,122],"SYHX2011","Enlonstobart","Squamous Non-small Cell Lung Cancer","First-Line Therapy","2026-06-24",{"date":68,"type":44},{"date":72,"type":23},{"date":127,"type":23},"2029-12-31",{"name":50,"class":51},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":52},"100571394","sd-rab-for-the-diagnosis-of-ppns-100571394","NCT06719687","Sd-RAB for the Diagnosis of PPNs","Self-driving Robotic-assisted Bronchoscopy for the Diagnosis of Peripheral Pulmonary Nodules","Inclusion Criteria:\n\n1. Patients older than 18 years old.\n2. Presence of a peripheral pulmonary nodule (8 mm \\\u003C diameter ≤ 30 mm) on thin-section chest CT that is suspected to be malignant and requires non-surgical biopsy.\n3. Patients have good medical adherence and signed informed consent.\n\nExclusion Criteria:\n\n1. Presence of contraindications to bronchoscopy under general anesthesia.\n2. Presence of concomitant endobronchial lesion during the bronchoscopy procedure.\n3. The investigators believe that patient has other conditions that are not suitable for the study.",{"count":137,"type":23},30,[26],"This is a single-center, prospective, and single-arm study. The purpose of this study is to evaluate the feasibility and safety of a new self-driving robotic-assisted bronchoscopic system for the diagnosis of peripheral pulmonary nodules.",[141],"Peripheral Pulmonary Nodules","2026-06-22",{"date":144,"type":44},"2026-06-25",{"date":146,"type":23},"2026-06",{"date":148,"type":23},"2027-01",{"name":50,"class":51},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":157,"targetDuration":4,"studyType":24,"phases":159,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":52},"100599962","phase-2-a-study-of-ql1706-combined-with-chemotherapy-induction-on-sequential-immunotherapy-consolidation-in-patients-with-limited-stage-small-cell-lung-cancer-after-chemoradiotherapy-100599962","NCT07091305","A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial","Inclusion Criteria:\n\n1. The patient must be aged between 18 and 75 years (inclusive of boundary values), and both males and females are eligible.\n2. Pathologically confirmed LS-SCLC\n3. Investigator confirmation of at least one measurable lesion, as defined by RECIST v1.1\n4. ECOG performance status of 0 or 1\n5. Forced expiratory volume in one second (FEV₁) \\> 1.0 L\n6. No clinically significant interstitial lung disease on baseline CT or PET\u002FCT.\n7. Adequate organ and bone-marrow function (all tests performed within 7 days prior to first dose; no transfusions, growth factors, albumin, or other corrective therapies within 14 days):Hemoglobin ≥ 90 g\u002FL, ANC ≥ 1.5 × 10⁹\u002FL, PLT ≥ 90 × 10⁹\u002FL,Serum creatinine ≤ 1.5 × ULN, TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN, Albumin (ALB) ≥ 25 g\u002FL,INR ≤ 1.5 × ULN, PT and APTT ≤ 1.5 × ULN (subjects on prophylactic anticoagulation must have values within a safe therapeutic range, per investigator)\n8. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use reliable contraception from screening until 3 months after the last dose; male subjects must agree to use effective contraception or have undergone surgical sterilization for the same period.\n9. No prior systemic anti-tumor therapy before enrollment.\n10. Estimated life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Known hypersensitivity to QL1706 or any of its excipients\n2. Histologically confirmed non-small cell lung cancer (NSCLC) or mixed tumor containing an NSCLC component.\n3. History of another primary malignancy or previous allogeneic organ transplantation.\n4. Surgery (other than diagnostic biopsy) within 4 weeks before first dose of study drug.\n5. Active substance abuse (e.g., illicit drug use), chronic alcoholism, AIDS, or known HIV infection.\n6. Active autoimmune disease, or history of autoimmune disease likely to recur. Systemic corticosteroid therapy equivalent to \\>10 mg\u002Fday prednisone (or other immunosuppressive therapies) within 14 days before first dose.\n7. Prior therapy with any antibody or agent targeting T-cell co-regulatory proteins (e.g., PD-1, PD-L1, CTLA-4, TIM-3, LAG-3).\n8. Interstitial lung disease (ILD), or history of ILD requiring steroid therapy. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonia on screening chest CT.\n9. Live vaccine administration within 28 days prior to first study drug dose. Any condition or comorbidity contraindicating chemo- or radiotherapy (e.g., active infection, myocardial infarction within 6 months, symptomatic heart disease including unstable angina, congestive heart failure, uncontrolled arrhythmia, ongoing immunosuppressive therapy).\n10. Pregnant or breastfeeding women; women of childbearing potential or men unwilling to use adequate contraception.\n11. Known hereditary bleeding diathesis or coagulation disorder.\n12. Prior malignancy, except adequately treated non-melanoma skin cancer, or in situ carcinoma (e.g., breast, oral, cervical) with expected survival \\>3 years.\n13. Any other medical, psychiatric, or laboratory abnormality that, in the investigator's judgment, could interfere with trial participation or interpretation of results.",{"count":158,"type":23},28,[114],"The study is being conducted to evaluation of the Efficacy and Safety of QL1706 Combined with Chemotherapy Induction in Sequential Immunotherapy Consolidation After Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer(LS-SCLC), and Exploration of the Correlation Between Biomarkers (PD-L1, TMB, ctDNA, etc.) Related to QL1706 Treatment and Treatment Efficacy and Prognosis.\n\nQL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.",[162,163,164,165],"Limited-stage Small Cell Lung Cancer (LS-SCLC)","Chemoradiotherapy","Induction Therapy","Consolidation Immunotherapy",[167,168,169,170,171],"Limited-stage small cell lung cancer","QL1706","chemoradiotherapy","induction therapy","consolidation immunotherapy","RECRUITING","2026-06-10",{"date":175,"type":44},"2026-06-11",{"date":177,"type":44},"2025-10-23",{"date":179,"type":23},"2028-08-01",{"name":50,"class":51},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":52},"100549741","phase-3-neoadjuvant-therapy-of-sbrt-sequencial-with-toripalimab-and-chemotherapy-in-resectable-stage-ii-iii-nsclc-patientsneor-torch-100549741","NCT06437977","Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients: A Multicenter, Openlabel, Randomized, Phase III Trial","neoR-TORCH","Inclusion Criteria:\n\n1. Aged 18 -75 years, regardless of gender；\n2. ECOG score 0-1;\n3. Treatment-naive, histologically confirmed resectable, stage II, IIIA, IIIB (N2) (AJCC staging system, version 8) NSCLC ;\n4. Measurable lesions based on the response evaluation criteria in solid tumors version 1.1;\n5. Tumor tissue specimens available for pathological diagnosis, detection of PD-L1 expression and biomarkers prior to randomization ;\n6. According to the doctor's judgment, lung function can meet the requirements of pneumonectomy;\n7. Confirming the absence of EGFR\u002FALK sensitive gene mutations through molecular pathological diagnosis of the organization;\n8. Good organ function:\n\n   Bone marrow function: absolute neutrophil count ≥ 1.5 × 109\u002FL, platelet count ≥ 80 × 109\u002FL, hemoglobin ≥9 g\u002FdL; Liver function: total bilirubin ≤ 1.5 × ULN, ALT and AST ≤ 1.5 × ULN; Renal function: serum creatinine ≤ 1.5 × ULN or serum creatinine clearance rate ≥ 60 mL\u002Fmin; blood urea nitrogen ≤ 200mg\u002FL;\n9. Having sufficient understanding of this study and being willing to sign the informed consent form; 10. For female subjects of childbearing age, the serum pregnancy test should be negative within 3 days before receiving the first dose (cycle 1, day 1).\n\nExclusion Criteria:\n\n1. Have locally advanced unresectable or metastatic disease; unresectable includes unresectable stage III non-small cell lung cancer as defined by the Multidisciplinary Diagnosis and Treatment Consensus (2019 edition), including partial stages IIIA and IIIB and all stage IIIC, N2: single station mediastinal lymph nodes with short diameter≥3cm or N2: multi-station mediastinal metastasis with lymph node fusion and the short diameter of lymph node ≥2cm on CT, T4 invading esophagus, heart, aorta, pulmonary veins and all the N3;\n2. NSCLC involving superior sulcus, large cell neuroendocrine carcinoma (LCNEC), sarcomatoid tumor;\n3. Participants with known EGFR sensitive mutations or ALK translocation, EGFR and ALK mutation status needs to be identified for the subjects with non-squamous cell carcinoma;\n4. Previous treatment with systemic antitumor therapy for early NSCLC, including investigational product;\n5. History of (non-infectious) pneumonitis\u002Finterstitial lung disease requiring steroid treatment, or ongoing pneumonitis\u002Finterstitial lung disease requiring steroid treatment;\n6. Active tuberculosis；\n7. Active infection requiring systemic treatment；\n8. Subjects with any known or suspected autoimmune disorder or immunodeficiency, with the following exceptions: hypothyroidism, hormone therapy is not needed, or well controlled at physiological dose; controlled type I diabetes;\n9. Uncontrolled active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] in screening period with HBV-DNA detected higher than the upper limit of normal at the clinical laboratory of the study center); (the subjects with HBV-DNA assay \\\u003C500 IU\u002FmL within 28 days prior to randomization who have received local standard antiviral therapy for at least 14 days and are willing to receive antiviral therapy continuously during the study can be enrolled); active hepatitis C (defined as positive hepatitis C surface antibody \\[HCsAb\\] in screening period and positive HCV-RNA);\n10. Known human immunodeficiency virus (HIV) infection (known positive HIV antibody);\n11. Vaccination of live vaccine within 30 days prior to the first dose. Including but not limited to the following: parotitis, rubella, measles, varicella\u002F herpes zoster (varicella), yellow fever, Rabies, Bacille Calmette-Guérin (BCG) and typhoid vaccine (inactivated virus vaccine allowed);\n12. ≥ grade 2 peripheral neuropathy；\n13. Previous use of PD-1\u002FPD-L1 agent or the drug acting on another targeted T cell receptor (e.g., CTLA-4, OX-40);\n14. Severe allergic reaction to other monoclonal antibodies;\n15. History of serious allergy to Pemetrexed, paclitaxel or docetaxel, cisplatin, carboplatin or its preventive medications;\n16. Known serious or uncontrolled pre-existing diseases; including but not limited to cardiovascular events with hemodynamic instability, symptomatic cerebrovascular events, and hepatic cirrhosis above Child-Pugh A within 6 months;\n17. History or current evidence of any disease, therapy or abnormal laboratory examination that may confuse the study results, interfere with subject's participation in the full course of the study or not meet the best interest of subject's participation in the study, as judged by investigators;\n18. Other malignant tumors within 5 years prior to the first dose, except non-small cell lung cancer. The malignant tumors with negligible risk of metastasis or death (e.g., expected disease-free survival \\> 5 years) and expected to achieve radical outcomes after treatment (e.g., sufficiently treated carcinoma in situ of cervix, basal or squamous cell skin cancer, ductal carcinoma in situ treated for radical surgery) can be excluded.",{"count":190,"type":23},478,[115],"This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.",[194],"Stage II-III Non-small Cell Lung Cancer","2026-05-08",{"date":197,"type":44},"2026-05-13",{"date":199,"type":44},"2024-09-12",{"date":201,"type":23},"2029-06",{"name":50,"class":51},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":209,"targetDuration":211,"studyType":87,"phases":4,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":52},"100636426","establishment-of-a-prospective-clinical-cohort-of-small-cell-lung-cancer-patients-receiving-radiotherapy-involved-comprehensive-treatment-100636426","NCT07565532","Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive Treatment","Inclusion Criteria:\n\nInclusion Criteria for Limited-Stage Small Cell Lung Cancer (LS-SCLC):\n\n1\\. Voluntary signed informed consent according to clinical routine practice. 2. Histologically and radiologically confirmed, previously untreated limited-stage SCLC (according to the Veterans Administration Lung Study Group staging system).\n\n3\\. Age ≥ 18 years. 4. Life expectancy ≥ 8 weeks. 5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. 6. At least one documented efficacy assessment. 7. At least one measurable lesion as confirmed by the investigator according to RECIST (iRECIST 2017) criteria.\n\n8\\. Adequate organ and bone marrow function, with laboratory tests performed within 7 days prior to the first dose meeting the following criteria (without receiving any blood components, hematopoietic growth factors, albumin, or other corrective therapies considered by the investigator within 14 days prior to laboratory assessments):\n\n1. Hematology: Hemoglobin (Hb) ≥ 90 g\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, platelet count (PLT) ≥ 90 × 10⁹\u002FL.\n2. Biochemistry: Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN); serum total bilirubin (TBIL) ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN in patients without liver metastases, or ≤ 5.0 × ULN in patients with liver metastases; serum albumin (ALB) ≥ 25 g\u002FL.\n3. Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for patients receiving prophylactic anticoagulation, the INR and APTT values should be judged by the treating physician or investigator to be within a safe and effective therapeutic range).\n\n9\\. Pulmonary function test showing FEV₁ \\> 0.75 L. 10. No evidence of severe interstitial lung disease confirmed by CT or PET\u002FCT prior to treatment.\n\n11\\. No prior or concurrent primary malignancy at other sites. 12. No requirement for PD-L1 expression level.\n\nInclusion Criteria for Extensive-Stage Small Cell Lung Cancer (ES-SCLC):\n\n1\\. Voluntary signed informed consent according to clinical routine practice. 2. Histologically confirmed SCLC with complete staging workup showing extensive-stage disease (according to the Veterans Administration Lung Study Group staging system).\n\n3\\. Age ≥ 18 years. 4. Life expectancy ≥ 8 weeks. 5. At least one documented efficacy assessment. 6. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2. 7. Adequate organ and bone marrow function, with laboratory tests performed within 7 days prior to the first dose meeting the following criteria (without receiving any blood components, hematopoietic growth factors, albumin, or other corrective therapies considered by the investigator within 14 days prior to laboratory assessments):\n\n1. Hematology: Hemoglobin (Hb) ≥ 90 g\u002FL, absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL, platelet count (PLT) ≥ 90 × 10⁹\u002FL.\n2. Biochemistry: Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN); serum total bilirubin (TBIL) ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 × ULN in patients without liver metastases, or ≤ 5.0 × ULN in patients with liver metastases; serum albumin (ALB) ≥ 25 g\u002FL.\n3. Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for patients receiving prophylactic anticoagulation, the INR and APTT values should be judged by the treating physician or investigator to be within a safe and effective therapeutic range).\n\n8\\. No severe concurrent medical illness. 9. Forced expiratory volume in one second (FEV₁) \\> 0.75 L. 10. For patients with prior radiotherapy to the primary lesion, the current radiotherapy target is limited to metastatic lesions.\n\n11\\. No prior or concurrent primary malignancy at other sites. 12. No requirement for PD-L1 expression level. 13. For patients with limited-stage SCLC who previously received curative-intent treatment, upon recurrence or metastasis, if complete staging workup is available and this is their first use of immunotherapy, they may still be considered for inclusion in the extensive-stage cohort.\n\nExclusion Criteria:\n\nExclusion Criteria for Limited-Stage Small Cell Lung Cancer (LS-SCLC):\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC).\n2. No efficacy assessment record, or missing efficacy assessment data.\n3. Presence of other primary malignancies; history of allogeneic organ transplantation.\n4. Major surgery (excluding diagnostic biopsy) within 4 weeks prior to the first dose.\n5. History of substance abuse (e.g., drug addiction), long-term alcoholism, or AIDS or HIV carrier.\n6. Active autoimmune disease, or history of autoimmune disease with potential for relapse.\n7. Current systemic corticosteroid therapy (e.g., equivalent to \\>10 mg prednisone daily) or use of any other form of immunosuppressive therapy within 14 days prior to the first dose.\n8. Prior treatment with any antibody\u002Fdrug targeting T-cell co-regulatory proteins (immune checkpoints), including but not limited to PD-1, PD-L1, CTLA-4, TIM-3, and LAG-3.\n9. Interstitial lung disease (ILD) or history of ILD requiring corticosteroid therapy.\n10. History of idiopathic pulmonary fibrosis (IPF), drug-induced pneumonitis, organizing pneumonia (e.g., bronchiolitis obliterans), idiopathic pneumonia, or evidence of active pneumonitis on screening chest CT.\n11. Receipt of live vaccine within 28 days prior to the first dose of study drug.\n12. Any other disease or condition that contraindicates chemoradiotherapy, including but not limited to active infection, within 6 months post-myocardial infarction, symptomatic heart disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmias), and immunosuppressive therapy.\n13. Unresolved toxicity of Grade 2 or higher (according to CTCAE version 5.0).\n14. Pregnant or breastfeeding women; men or women of childbearing potential who are unwilling to use adequate contraceptive measures.\n15. Evidence of inherited bleeding diathesis or coagulation disorders.\n16. Prior history of malignancy (excluding skin cancer, or in situ breast cancer, oral cancer, or cervical cancer with life expectancy \\>3 years).\n\nExclusion Criteria for Extensive-Stage Small Cell Lung Cancer (ES-SCLC):\n\n1. Pulmonary carcinoid or non-small cell lung cancer, unless transformed SCLC is ruled out.\n2. No efficacy assessment record, or missing efficacy assessment data.\n3. History of severe anaphylactic\u002Fallergic reaction to humanized antibodies or fusion proteins.\n4. Acute exacerbation of chronic obstructive pulmonary disease (COPD) or other pulmonary diseases requiring hospitalization.\n5. Active or prior autoimmune disease (within the past 2 years) or history of primary immunodeficiency.\n6. Progression after immunotherapy; prior or concurrent diagnosis of any other malignancy, excluding non-melanoma skin cancer or carcinoma in situ of the cervix.\n7. Any other disease or condition that contraindicates chemoradiotherapy, including but not limited to active infection, within 6 months post-myocardial infarction, symptomatic heart disease (including unstable angina, congestive heart failure, or uncontrolled arrhythmias), or immunosuppressive therapy.\n8. Unresolved toxicity of Grade 2 or higher (according to CTCAE version 5.0).\n9. Current or prior history of autoimmune disease or immunodeficiency, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, and rheumatoid arthritis.\n10. History of idiopathic pulmonary fibrosis (IPF), organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonia; or evidence of active pneumonitis on chest CT scan. Patients with a history of radiation pneumonitis (fibrosis) within the radiation field may be enrolled.\n11. Pregnant or breastfeeding women; men or women of childbearing potential who are unwilling to use adequate contraceptive measures.",{"count":210,"type":23},500,"2 Years","By establishing a prospective clinical cohort for small cell lung cancer (SCLC) and systematically collecting high-quality real-world data integrating clinical, imaging, pathological, and molecular dimensions, this study aims to enable personalized treatment for distinct SCLC subtypes. Furthermore, by evaluating the influence of radiotherapy timing, dose and fractionation, and target selection on efficacy and toxicity, we aim to identify the optimal radio-immunotherapy combination regimen that maximizes the synergistic effect in SCLC patients.",[214,215,216,217],"Small Cell Lung Cancer ( SCLC )","Radiotherapy","Immunotherapy","Personalized Cancer Treatment",[219,215,216,217],"Small Cell Lung Cancer (SCLC)","2026-04-27",{"date":222,"type":44},"2026-05-04",{"date":224,"type":44},"2026-04-01",{"date":226,"type":23},"2030-03-31",{"name":50,"class":51},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":236,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":239,"conditions":240,"keywords":245,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":255,"leadSponsor":257,"locationsCount":52},"100636351","septum-guided-segmentectomy-for-deep-early-stage-lung-cancer-sgs2512-100636351","NCT07564557","Septum-guided Segmentectomy for Deep Early-stage Lung Cancer (SGS2512)","Effectiveness and Safety of Septum-guided Segmentectomy in Solid-dominant, Deep-seated Early-stage Non-small Cell Lung Cancer (≤2 cm): A Single-center, Prospective, Single-arm Clinical Trial","SGS2512","Inclusion Criteria:\n\n* Age 18-80 years\n* Clinical stage IA (cT1a-bN0M0)\n* tumor diameter ≤ 2 cm\n* Pathological feature: Solid-dominant lesion (CTR \\> 0.5)\n* Tumor location: Deep-seated within the lung parenchyma (inner 2\u002F3), defined as the tumor center being located in the inner 2\u002F3 region of the lung field on axial, coronal, and sagittal CT views\n* ECOG Performance Status: 0-1\n* Pulmonary function: FEV1 ≥ 60% predicted and DLCO SB ≥ 60% predicted\n* Participants must be willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Multiple pulmonary nodules or evidence of distant metastasis\n* Intraoperative confirmation of lymph node metastasis (N1\u002FN2) or pleural dissemination\n* History of previous ipsilateral lung surgery\n* History of other malignant tumors within the past 5 years\n* Presence of severe cardiovascular or cerebrovascular diseases that preclude surgical tolerance\n* Pregnancy or breastfeeding",{"count":237,"type":23},89,[26],"The purpose of this study is to evaluate the safety and effectiveness of a specialized surgical technique called \"Septum-guided Segmentectomy\" for treating early-stage lung cancer located deep within the lung tissue.Standard surgery for lung cancer often involves removing an entire lung lobe (lobectomy), which can significantly reduce a patient's breathing capacity. For small tumors, removing only a segment of the lung (segmentectomy) can preserve more healthy tissue. However, for tumors located deep in the lung, traditional segmentectomy is technically challenging and risks leaving cancer cells behind.In this study, surgeons will use the natural anatomical boundaries-the intersegmental veins and their surrounding thin membranes (septa)-as a guide to precisely remove the target lung segment. This \"septum-guided\" approach aims to ensure the cancer is completely removed while maximizing the preservation of healthy lung function.Participants will be followed for 3 years after surgery to monitor for cancer recurrence and assess their long-term recovery.",[241,242,243,244],"Non-small Cell Lung Cancer","Early-stage Lung Cancer","Deep-seated Lung Nodules","Solid-dominant Lung Cancer",[246,247,248,249,250,251,234],"Septum-guided Segmentectomy","Intersegmental Septum","VATS Segmentectomy","Precision Surgery","Lung-sparing Surgery","Anatomical Boundary","2026-04-26",{"date":222,"type":44},{"date":224,"type":44},{"date":256,"type":23},"2031-04-01",{"name":50,"class":51},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":52},"100635159","phase-2-vebreltinib-plus-chemotherapy-as-first-line-treatment-for-met-overexpressing-nsclc-100635159","NCT07549061","Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC","A Phase II Study of Vebreltinib Combined With Platinum-Doublet Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Negative Driver Genes and MET Overexpression","Inclusion Criteria:\n\n1. Voluntarily sign a written informed consent form (ICF) to participate in the study; be willing and able to comply with study-related visits and procedures.\n2. Male or female subjects aged 18 years or older.\n3. Pathologically confirmed non-small cell lung cancer (NSCLC); outside hospital pathology reports are acceptable.\n4. Newly diagnosed metastatic NSCLC (clinical Stage IVA or IVB) or recurrent NSCLC (staged in accordance with the AJCC Cancer Staging Manual 9th edition), not eligible for curative-intent surgery or radiotherapy.\n5. Treatment-naïve advanced NSCLC not amenable to curative surgery or radiotherapy. For recurrent disease, prior adjuvant and neoadjuvant therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiotherapy\u002Fchemoradiotherapy with or without immunotherapy, biologic therapy, or investigational agents is permitted if completed at least 12 months before disease recurrence.\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-2.\n7. Driver gene-negative status confirmed by tumor tissue or blood sample, including but not limited to negative EGFR mutation, negative ALK rearrangement, negative ROS1 rearrangement, negative KRAS G12C mutation, and negative MET exon 14 skipping mutation. MET amplification is permitted: FISH demonstrating GCN ≥ 4 or MET\u002FCEP7 ≥ 2, or positive result confirmed by NGS.\n8. MET protein overexpression defined as ≥50% of tumor cells staining at IHC 2++ or stronger. Local laboratory IHC results are acceptable.\n9. Estimated overall survival of at least 3 months.\n10. Laboratory values meeting the following requirements:\n\n    Absolute neutrophil count (ANC)≥1.5 × 10⁹\u002FL; Hemoglobin≥90 g\u002FL; Platelets≥75 × 10⁹\u002FL; Serum total bilirubin≤1.5×upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤3×ULN; for patients with liver metastases, AST and ALT≤5×ULN; Serum creatinine\\\u003C1.5 × ULN. Creatinine clearance (CrCl)\\>50 mL\u002Fmin, calculated using the Cockcroft-Gault formula\n11. Males with reproductive potential and females of childbearing potential must agree to use highly effective contraception from signing informed consent until 3 months after the last dose of study drug. For females of childbearing potential, a serum pregnancy test must be negative within ≤7 days before the first dose of study drug.\n\nExclusion Criteria:\n\n1. Spinal cord compression. Symptomatic or unstable brain metastases, unless the patient has completed curative treatment, is not receiving corticosteroid therapy, and has maintained a stable neurological status for at least 2 weeks after completion of curative treatment and steroid therapy. Patients with asymptomatic brain metastases may be included if the investigator determines there is no immediate indication for curative treatment.\n2. Meeting any of the following prior treatment history criteria:\n\n   Major surgery (e.g., intrathoracic, intra-abdominal, or intrapelvic surgery) within 4 weeks prior to enrollment, or failure to recover from side effects of such surgery. Thoracoscopic biopsy and mediastinoscopy are not considered major surgery, and patients may be enrolled 1 week after these procedures.\n\n   Treatment with traditional Chinese medicine (TCM) or Chinese patent medicine with anti-tumor indications within 1 week prior to the first dose of study drug.\n\n   Treatment with strong CYP3A4 inducers and\u002For strong inhibitors, and inability to discontinue such agents for at least 1 week prior to initiation of study treatment and during the study period.\n\n   Prior systemic anti-tumor therapy for advanced NSCLC, including chemotherapy, biologic therapy, immunotherapy, or any investigational agent, administered as non-curative surgery or radiotherapy. For recurrent disease, prior adjuvant and neoadjuvant therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, investigational agents), or definitive radiotherapy\u002Fchemoradiotherapy with or without immunotherapy, biologic therapy, or investigational agents is permitted only if completed at least 12 months before disease recurrence.\n\n   Radiation therapy to more than 30% of bone marrow, or large-field radiation therapy within 4 weeks prior to the first dose of vebreltinib.\n\n   Patients with intracranial lesions requiring urgent local treatment for symptom relief are recommended for exclusion, at the discretion of the investigator.\n\n   Any severe or uncontrolled systemic disease, including but not limited to other severe medical or psychiatric disorders or laboratory abnormalities that, in the investigator's judgment, render the study drug inappropriate for the patient or impair compliance with the protocol.\n3. Meeting any of the following cardiac function or disease criteria:\n\n   Mean corrected QT interval (QTc) \\> 470 ms based on three routine ECG assessments performed at least 5 minutes apart (preferably completed within 1 hour) during the screening period at rest. Calculation shall be performed using the Fridericia formula (see Appendix 5 for details), with mean QTcF \\> 470 ms.\n\n   Any significant cardiac arrhythmia, such as complete left bundle branch block, second- or third-degree heart block, ventricular arrhythmia, drug-uncontrolled supraventricular or nodal arrhythmia, or other drug-uncontrolled cardiac arrhythmias.\n\n   Any risk factors for prolonged QTc interval, including chronic hypokalemia uncorrected by supplementation, congenital long QT syndrome, and concomitant use of QTc-prolonging medications.\n\n   Congestive heart failure of New York Heart Association (NYHA) Class ≥3. Unstable or uncontrolled diseases or conditions related to or affecting cardiac function (e.g., unstable angina pectoris, inadequately controlled hypertension defined as diastolic blood pressure \\> 100 mmHg and\u002For systolic blood pressure \\> 160 mmHg regardless of antihypertensive use; initiation or adjustment of antihypertensive agents prior to screening is permitted).\n4. Diagnosis of another active malignancy requiring treatment within the past 3 years, other than NSCLC. Excluded are completely resected basal cell and squamous cell skin cancer, and completely resected carcinoma in situ of any type.\n5. Presence of active infection, including but not limited to:\n\n   Chronic hepatitis B (hepatitis B surface antigen \\[HBsAg\\] positive with hepatitis B virus \\[HBV\\] DNA ≥ 500 IU\u002Fml), hepatitis C (positive anti-hepatitis C virus \\[HCV\\] antibody and positive HCV-RNA), human immunodeficiency virus (HIV) infection (positive HIV antibody), or syphilis infection.\n\n   Active tuberculosis. Active infection requiring systemic anti-infective therapy (e.g., pneumonia) within 2 weeks prior to the first dose of study drug.\n\n   History of interstitial lung disease (ILD), drug-induced ILD, or radiation pneumonitis requiring corticosteroid therapy; or current active interstitial lung abnormalities requiring medical therapy or other clinical intervention.\n\n   Active gastrointestinal disorders (e.g., ulcerative lesions, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome) or other conditions (e.g., inability to swallow study medication, prior major gastrointestinal surgery) that may significantly affect absorption, distribution, metabolism, or excretion of oral study drug.\n6. Known hypersensitivity to drugs of the same class as the study drug or to any of its excipients.\n7. Any concurrent medical condition that may increase the risk of toxicity.\n8. Pregnant or lactating females.\n9. Current participation in another clinical trial, or receipt of investigational product within 2 weeks prior to the first dose of study drug.\n10. Any other circumstances deemed by the investigator to render the patient ineligible for study participation, including evidence of severe or uncontrolled systemic disease such as active primary immunodeficiency disorders and allogeneic organ transplantation, which would make the patient unsuitable for enrollment or interfere with compliance with the study protocol.",{"count":266,"type":23},19,[114],"To explore the efficacy and safety of vebreltinib plus platinum-doublet chemotherapy as first-line therapy in patients with driver gene-negative, locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression.",[270],"Lung Neoplasms",[272,273,274,275],"NSCLC","Vebreltinib","Met","Overexpression","2026-04-23",{"date":278,"type":44},"2026-04-29",{"date":280,"type":23},"2026-03-30",{"date":282,"type":23},"2028-12-30",{"name":50,"class":51},{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":24,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":52},"100634851","robotic-assisted-bronchoscopy-guided-synchronous-biopsy-and-radiofrequency-ablation-for-pulmonary-nodules-100634851","NCT07545057","Robotic-Assisted Bronchoscopy-Guided Synchronous Biopsy and Radiofrequency Ablation for Pulmonary Nodules","A Feasibility Study on Synchronous Biopsy and Radiofrequency Ablation for Pulmonary Nodules Under Robotic-Assisted Bronchoscopy: A Prospective, Single-Arm, Open-Label Clinical Study：ROBUST Study","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Chest CT indicates pulmonary nodules, highly suspected of being malignant;\n* Size of pulmonary nodules: 8 mm \\\u003C maximum diameter ≤ 30 mm, and the number of pulmonary nodules requiring intervention ≤ 3;\n* Preoperative imaging evaluation indicates no clear lymph node metastasis or distant metastasis (cT1N0M0);\n* Multidisciplinary evaluation shows that the patient cannot tolerate surgery and radiotherapy, or the patient refuses surgery and radiotherapy after full informed consent;\n* The patient understands and agrees to receive synchronous biopsy and ablation treatment under robotic-assisted bronchoscopy and signs a written informed consent form.\n\nExclusion Criteria:\n\n* Patients who cannot tolerate general anesthesia due to advanced age or severe cardiopulmonary diseases, or other reasons;\n* The target nodule has been diagnosed as a malignant tumor or metastasis;\n* Patients with severe bleeding tendency or uncorrectable coagulation disorder (platelet count \\\u003C 50×10\\^9 \u002FL, prothrombin time \\> 18s, prothrombin activity \\\u003C 40%);\n* Severe pulmonary fibrosis and pulmonary hypertension;\n* Anticoagulant or anti-platelet drugs have not been discontinued for the required time before surgery;\n* Implanted cardiac pacemaker, defibrillator, or other electronic implants;\n* Presence of important blood vessels that cannot be avoided along the biopsy path;\n* Other conditions that the investigators consider not suitable for the patient to participate in this study.","100 Years",{"count":293,"type":23},76,[26],"This is a prospective, single-arm, open-label clinical study. The primary study objective is to evaluate the feasibility of synchronous biopsy and radiofrequency ablation for pulmonary nodules under robotic-assisted bronchoscopy.",[297],"Pulmonary Nodules","2026-04-22",{"date":300,"type":44},"2026-04-28",{"date":302,"type":23},"2026-05-01",{"date":304,"type":23},"2027-12-31",{"name":50,"class":51},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":316,"conditions":317,"keywords":322,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":337},"100634579","rats-sleeve-lobectomy-after-neo-chemo-io-for-nsclc-100634579","NCT07541521","RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC","Robotic-Assisted Sleeve Lobectomy for Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy","RIDDLE-NSCLC","Inclusion Criteria:\n\n* Age ≥18 years\n* ECOG performance status 0-2\n* Histologically confirmed NSCLC\n* AJCC 9th clinical stage IIB-III, M0, deemed resectable or potentially resectable by the multidisciplinary tumour discussion (MDT)\n* Planned neoadjuvant chemo-immunotherapy (PD-1\u002FPD-L1 inhibitor + platinum doublet；additional neoadjuvant thoracic radiotherapy is allowed)\n* Planned curative-intent RATS sleeve lobectomy with systematic nodal dissection\n* Baseline and restaging imaging per protocol (CT ± PET-CT)\n* Complete 30-day postoperative follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Metastatic disease (M1) at baseline or on restaging.\n* No immunotherapy component in neoadjuvant regimen (pure chemotherapy) .\n* Prior systemic therapy or thoracic radiotherapy for the current cancer before starting chemo-IO.\n* Palliative intent or planned non-anatomic resection only (e.g., wedge) when sleeve\u002Flobectomy is indicated oncologically.\n* Clear unresectability at restaging (e.g., multistation bulky N2\u002FN3 not responding; unreconstructable T4 invasion) or MDT consensus against surgery.\n* Contraindication to general anesthesia or prohibitive cardiopulmonary risk precluding sleeve\u002Flobectomy.\n* Active autoimmune disease requiring systemic immunosuppression within 2 years, prior organ transplant, or history of grade ≥2 pneumonitis\u002FILD\n* Uncontrolled infection, pregnancy or breastfeeding, or any intercurrent illness that would compromise participation.",{"count":315,"type":23},100,"The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. The main questions it aims to answer are:\n\nWhat is the rate of unsuccessful robotic-assisted sleeve lobectomy after neoadjuvant chemoimmunotherapy?\n\nWhat factors are associated with unsuccessful surgery?\n\nHow do surgeons subjectively assess intraoperative difficulty across multiple dimensions during these procedures?\n\nIn this study, unsuccessful surgery is defined as any of the following: conversion to thoracotomy, incomplete (non-R0) resection, or major postoperative complications. Participants who are scheduled to undergo curative-intent robotic-assisted sleeve lobectomy as part of their routine clinical care after neoadjuvant chemoimmunotherapy will be enrolled from multiple centers. Clinical, intraoperative, pathological, and short-term postoperative data will be collected prospectively. In addition, surgeons will be asked to provide a multidimensional subjective assessment of intraoperative difficulty, including factors such as pleural adhesions, hilar fibrosis, nodal matting, fissure completeness, and vascular inflammation or edema, to better characterize the technical challenges of surgery and their association with perioperative outcomes.",[318,319,320,321],"Stage IIB-III NSCLC","Sleeve Lobectomy","Robotic Surgery","Neoadjuvant Chemoimmunotherapy",[323,324,325,326,327,328],"stage IIB-III NSCLC","sleeve lobectomy","robotic surgery","neoadjuvant chemoimmunotherapy","perioperative outcomes","difficulty of surgery","2026-04-16",{"date":331,"type":44},"2026-04-21",{"date":333,"type":23},"2026-04-13",{"date":335,"type":23},"2027-05-30",{"name":50,"class":51},10,{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":52},"100632541","electroacupuncture-plus-5-ht3-receptor-inhibitor-for-ponv-prevention-in-high-risk-patients-undergoing-thoracoscopic-lung-cancer-surgery-100632541","NCT07515027","Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery","Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* American Society of Anesthesiologists (ASA) physical status I-III;\n* Body mass index (BMI) 18-30 kg\u002Fm²;\n* Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection;\n* Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3;\n* Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities;\n* No infection around the acupuncture sites;\n* Voluntary written informed consent provided by the subject.\n\nExclusion Criteria:\n\n* Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function;\n* Subjects with cognitive dysfunction or psychological disorders;\n* History of previous esophageal or gastric surgery;\n* Hypersensitivity to acupuncture or any study medications;\n* Severe infection or history of surgery around the acupuncture sites;\n* Pregnant or lactating women;\n* Long-term opioid use;\n* Conversion to open surgery;\n* Acupuncture treatment received within 1 month prior to enrollment.",{"count":346,"type":23},204,[26],"This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.",[350],"PONV",[350,352,353],"EA","VATS","2026-04-07",{"date":333,"type":44},{"date":354,"type":23},{"date":358,"type":23},"2026-12-31",{"name":50,"class":51},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":337},"100633544","downstaging-and-rats-after-neo-chemo-io-impact-on-surgical-outcomes-in-nsclc-100633544","NCT07528066","Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC","The Impact of Downstaging on Robotic Surgical Outcomes After Neoadjuvant Chemo-Immunotherapy in Non-Small Cell Lung Cancer","DRAGON-NSCLC","Inclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed NSCLC\n* AJCC 9th clinical stage IIB-III, M0, deemed resectable or potentially resectable by the multidisciplinary tumour discussion (MDT)\n* Planned neoadjuvant chemo-immunotherapy (PD-1\u002FPD-L1 inhibitor + platinum doublet; additional neoadjuvant RT is allowed) with curative-intent surgery\n* Received ≥1 cycle of chemo-IO (capture the intended 2-4 cycles)\n* Baseline chest CT±PET-CT within 6 weeks before starting neoadjuvant therapy\n* Restaging 2-6 weeks after last neoadjuvant dose with chest CT±PET-CT\n* Curative-intent resection planned; surgery performed 2-10 weeks after last dose\n* Performing systematic nodal dissection\n* ECOG performance status 0-2.\n* Complete 90-day postoperative follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Metastatic disease (M1) at baseline or on restaging\n* No immunotherapy component in the neoadjuvant regimen (unless enrolled in a prespecified comparator cohort; otherwise exclude from primary analysis)\n* Prior systemic therapy or thoracic radiotherapy for the current lung cancer before starting neoadjuvant chemo-IO\n* Planned neoadjuvant chemoradiation (exclude unless including immunotherapy)\n* Definitive decision against surgery before starting neoadjuvant therapy\n* Active autoimmune disease requiring systemic immunosuppression within 2 years, prior organ transplant, or history of grade ≥2 pneumonitis\u002FILD\n* Uncontrolled infection, pregnancy\u002Flactation, or any condition precluding curative-intent resection per MDT",{"count":369,"type":23},200,"The goal of this observational study is to learn whether tumor and nodal downstaging after neoadjuvant chemo-immunotherapy is associated with better surgical outcomes in patients with clinical stage IIB-III non-small cell lung cancer (NSCLC) undergoing robotic-assisted thoracic surgery. The main question it aims to answer is:\n\nIs downstaging after neoadjuvant chemo-immunotherapy associated with better surgical outcomes in patients with stage IIB-III NSCLC undergoing robotic-assisted surgery?\n\nParticipants with resectable or potentially resectable stage IIB-III NSCLC who receive neoadjuvant chemo-immunotherapy as part of their routine clinical care and then undergo curative-intent robotic-assisted surgery will be prospectively enrolled from international centers. Clinical, operative, pathological, and postoperative outcome data will be collected, including R0 resection, the extent of resection, conversion to open surgery, postoperative complications, length of stay, readmission, and mortality.",[321,372,318],"Robotic Pulmonary Resection",[323,374,375,327],"neoadjuvant chemo-immunotherapy","robotic-assisted surgery",{"date":377,"type":44},"2026-04-14",{"date":379,"type":44},"2026-03-02",{"date":381,"type":23},"2027-03-30",{"name":50,"class":51},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":24,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":52},"100554796","transthoracic-vs-transbronchial-radiofrequency-ablation-for-lung-cancer-100554796","NCT06503744","Transthoracic vs Transbronchial Radiofrequency Ablation for Lung Cancer","Transthoracic Versus Transbronchial Radiofrequency Ablation for Peripheral Lung Cancer Staging IA: a Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age greater than 18 years.\n2. Primary peripheral lung cancer diagnosed by pathology and pre-procedure staging examination suggesting clinical stage T1N0M0, stage IA (including postoperative new and multiple primary).\n3. The proposed ablation lesion was evaluated for feasibility of CT and bronchoscopy-guided ablation treatment.\n4. Consent to initial ablation therapy is given after assessment of unsuitability for surgery or refusal of surgery and signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients with platelets \\\u003C50×109\u002FL, severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term.\n2. Patients with severe pulmonary fibrosis and pulmonary arterial hypertension.\n3. Infectious and radioactive inflammation around the lesion, skin infection at the puncture site that is not well controlled, systemic infection, high fever \\>38.5°C.\n4. Patients with severe hepatic, renal, cardiac, pulmonary and cerebral insufficiency, severe anaemia, dehydration and serious disorders of nutritional metabolism that cannot be corrected or improved in the short term.\n5. Those with poorly controlled malignant pleural effusions.\n6. Anticoagulation therapy and\u002For anti-platelet drugs (except dabigatran, rivaroxaban and other new oral anticoagulants) have not been discontinued more than 5\\~7d before ablation.\n7. Eastern Cooperative Oncology Group (ECOG) score \\>2.\n8. Combination of other tumours with extensive metastases and an expected survival of \\\u003C6 months.\n9. Patients with episodic psychosis.\n10. Patients with implanted electronic devices (e.g. pacemakers or defibrillators).\n11. Pregnant women, or patients with a pregnancy planned during the study period.\n12. Have participated or are participating in other clinical studies within the last 30 days.\n13. Any other condition that the investigator considers inappropriate for participation in this study.",{"count":391,"type":23},110,[26],"The aim of this study is to investigate the efficacy and safety of transthoracic versus transbronchial ablation in the treatment of early stage peripheral lung cancer.",[395],"Lung Cancer Stage IA","2026-04-06",{"date":333,"type":44},{"date":399,"type":44},"2024-01-04",{"date":401,"type":23},"2028-12",{"name":50,"class":51},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":24,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":103},"100590055","rab-versus-ultrathin-bronchoscopy-with-vbn-in-the-diagnosis-of-ppns-100590055","NCT06962436","RAB Versus Ultrathin Bronchoscopy With VBN in the Diagnosis of PPNs","Robotic-Assisted Bronchoscopy Versus Ultrathin Bronchoscope Combined With Virtual Bronchoscopic Navigation for the Diagnosis of Peripheral Pulmonary Nodules: A Prospective, Multicenter, Randomized Controlled，Non-inferiority Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of gender;\n2. Patients with peripheral lung nodules of suspected malignancy on chest CT who require non-surgical biopsy;\n3. Patients who voluntarily consent to undergo bronchoscopy and meet the requirements for the bronchoscopy;\n4. Patients should understand the purpose of the trial, demonstrate good compliance with the examinations and follow-ups, and voluntarily participate in the clinical trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Presence of contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmias; uncorrectable bleeding tendencies or severe coagulation disorders (such as platelet count \\\u003C60×10\\^9\u002FL), uremia; severe pulmonary artery hypertension; severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular events; aortic dissection or aneurysm; multiple bullae; extreme systemic exhaustion;\n2. Patients with pure ground-glass nodules suspected of malignancy on chest CT;\n3. Female patients who are breastfeeding, pregnant, or planning pregnancy;\n4. Patients with electromagnetic active implantable medical devices;\n5. Subjects allergic to anesthetics; or with a history of multiple severe allergies, hereditary allergy history;\n6. Those who have participated in or are currently participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days;\n7. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.",{"count":411,"type":23},186,[26],"The purpose of this study is to evaluate whether the diagnostic yield of robotic-assisted bronchoscopy is not inferior to that of the virtual bronchoscopic navigation combined with ultrathin bronchoscopy.",[141],"2026-03-20",{"date":417,"type":44},"2026-03-25",{"date":419,"type":44},"2025-07-02",{"date":421,"type":23},"2026-12",{"name":50,"class":51},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":24,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":52},"100581328","cryoablation-vs-thoracoscopic-surgery-for-ggn-100581328","NCT06848881","Cryoablation vs Thoracoscopic Surgery for GGN","Cryoablation Versus Thoracoscopic Surgery for Pulmonary Ground-Glass Nodules: A Prospective, Comparative, Open Label Study","Inclusion Criteria:\n\n1. Patients ≥ 18 years old.\n2. The size of the GGN is 8-20mm (with less than 25% solid component), and the number of nodules requiring treatment in the short term is less than 3.\n3. Pathological confirmation of the GGN as non-small cell lung cancer; or progression of the GGN during at least 3 months of follow-up, including enlargement of the largest diameter, increase in solid component, or the appearance of a significant solid component in a previously pure GGN, with multidisciplinary discussion (including radiology, thoracic surgery, and pulmonology) suggesting malignancy.\n4. No lymph node, pulmonary, or distant metastasis to other organs.\n5. After multidisciplinary evaluation, the patient is considered capable of tolerating both surgical and ablation procedures.\n6. Unsuitable for radiation therapy or refusal of radiation therapy.\n7. Willing to participate in this clinical study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients in poor general condition, with ECOG physical fitness score \\>2, unable to tolerate surgery or ablation therapy, or with relevant contraindications.\n2. Patients who have previously received other treatments for pulmonary GGNs.\n3. Patients with poor compliance.\n4. Severe heart, lung, kidney, brain, or other vital organ diseases.\n5. Active bacterial or fungal infections.\n6. Simultaneous or metachronous (within the past 5 years) double cancers.\n7. Women during pregnancy or breast-feeding.\n8. History of radiation therapy.\n9. Bleeding tendency, abnormal coagulation functions, or coagulation disorders that cannot be corrected after treatment.\n10. Contraindications to general anesthesia.\n11. Expected survival time \\\u003C 6 months.\n12. The researcher believes that it is not suitable for inclusion.",{"count":431,"type":23},160,[26],"The aim of this study is to investigate the efficacy and safety of Cryoablation and Thoracoscopic Surgery in the treatment of pulmonary ground-glass nodules.",[435],"Ground-Glass Opacity","2026-03-18",{"date":415,"type":44},{"date":439,"type":44},"2025-04-20",{"date":441,"type":23},"2030-04-15",{"name":50,"class":51},{"id":444,"slug":445,"hasResults":12,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":450,"targetDuration":4,"studyType":24,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":464,"leadSponsor":466,"locationsCount":4},"100629819","phase-2-neoadjuvant-adebrelimab-plus-crt-for-locally-advanced-thymic-carcinoma-100629819","NCT07479628","Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","A Single-Arm, Prospective, Phase II Trial of Adebrelimab Plus Albumin-Bound Paclitaxel, Cisplatin, and Concurrent Radiotherapy for Neoadjuvant Treatment of Locally Advanced Thymic Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤ 75 years old at the time of signing the informed consent form, both male and female are eligible.\n2. Histologically confirmed thymic carcinoma.\n3. Potentially resectable locally advanced (T3\u002F4NxM0). No previous treatment for thymic carcinoma, including but not limited to surgery, local radiotherapy, chemotherapy, immunotherapy, targeted drug therapy, and other investigational drug therapy.\n4. At least one measurable lesion according to RECIST 1.1 criteria.\n5. ECOG PS score: 0-1.\n6. Expected survival ≥ 3 months.\n7. Important organ functions must meet the following standards:\n\n1\\) Blood routine test: (No blood transfusion or use of G-CSF and other cytokine drugs for correction within 2 weeks before screening);\n\n1. Hemoglobin (HB) ≥ 90 g\u002FL;\n2. Absolute neutrophil count (ANC) ≥ 1.5×109\u002FL;\n3. Platelet count (PLT) ≥ 90×109\u002FL;\n4. White blood cell count (WBC) ≥ 3.0×109\u002FL and \\\u003C 15×109\u002FL; 2) Other tests: (No human albumin injection within 14 days before screening);\n\na) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3×ULN; b) Total bilirubin (TBIL) ≤ 1.5×ULN; c) Albumin (ALB) ≥ 30 g\u002FL; d) Creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance rate (CrCL) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); e) Thyroid stimulating hormone (TSH) ≤ 1×ULN (If TSH is abnormal, FT3\u002FT3 and FT4\u002FT4 levels should also be examined. If FT3\u002FT3 and FT4\u002FT4 are normal, the patient can be enrolled); f) Activated partial thromboplastin time (APTT) ≤ 1.5×ULN, international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5×ULN (No anticoagulant therapy); g) Left ventricular ejection fraction (LVEF) ≥ 50%. 8. Non-surgically sterilized or female patients of childbearing age must have a negative serum pregnancy test within 3 days before the first dose of the study drug and must not be lactating. Female patients of childbearing age or male patients whose partners are of childbearing age must agree to use highly effective contraceptive methods during the study and for 6 months after the last administration of the study drug.\n\n9\\. Patients must voluntarily join this clinical study, sign the informed consent form, have good compliance, and be able to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Patients with pathologies of thymoma or thymic neuroendocrine tumor.\n2. Patients with other malignant tumors within the past 3 years or concurrently, except for those with cured skin basal cell carcinoma, superficial bladder cancer, skin squamous cell carcinoma, cervical carcinoma in situ, and ductal carcinoma in situ of the breast.\n3. Patients with interstitial pneumonia\u002Finterstitial lung disease (excluding those with only imaging changes), those requiring systemic glucocorticoid treatment for pneumonia (such as radiation-induced pneumonia, etc.), those with active pneumonia or severe lung function impairment confirmed by pulmonary function tests.\n4. Patients with any active or known autoimmune diseases (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, hyperthyroidism, etc.). Patients with type 1 diabetes on stable insulin therapy, hypothyroidism requiring only hormone replacement therapy, and skin diseases (such as eczema, vitiligo or psoriasis) that do not require systemic treatment and have not had acute exacerbation within 1 year before screening are allowed to be enrolled. Patients with asthma requiring medical intervention with bronchodilators cannot be included.\n5. Patients with active pulmonary tuberculosis. Those who have received adequate treatment and have stopped anti-tuberculosis treatment for at least 3 months before treatment can be enrolled.\n6. Patients with uncontrolled clinical symptoms or diseases of the heart, such as: (1) New York Heart Association (NYHA) class 2 or higher heart failure (2) Unstable angina pectoris (3) Myocardial infarction within 1 year (4) Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.\n7. Patients who have experienced severe infections within 1 month before the start of treatment, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; patients with any active infections, or those with unexplained fever \\> 38.5°C during the screening period or before the first dose.\n8. Patients with a known positive history of human immunodeficiency virus (HIV) test or acquired immune deficiency syndrome (AIDS). Patients with active viral hepatitis (for hepatitis B: positive HBsAg and HBV DNA test value exceeds 500 IU; for hepatitis C: positive HCV antibody and HCV virus titer test value exceeds the upper limit of normal).\n9. Patients with known allergic reactions to adebiralimab or other PD-(L)1 monoclonal antibodies, or with a history of severe allergies to paclitaxel and platinum-based drugs or their prophylactic medications.\n10. Patients who have undergone major surgical procedures, systemic chemotherapy, immunotherapy, or other clinical trial drugs within 4 weeks before treatment; those who have received palliative radiotherapy within 2 weeks before treatment; those who have taken oral molecular targeted drugs and have stopped for less than 5 half-lives before treatment; or those who have used antibiotics within 1 week before treatment; and those who have not recovered from the toxicity and\u002For complications of previous interventions to NCI-CTCAE ≤ grade 1 (except for alopecia and fatigue, and the indicators mentioned in the inclusion criteria).\n11. According to the researcher's judgment, participants with other factors that may affect the research results or lead to the premature termination of this study, such as alcoholism, drug abuse, substance misuse, other serious diseases (including mental disorders) requiring combined treatment, severe laboratory test abnormalities, or those with family or social factors that may affect medication safety, will be excluded.",{"count":451,"type":23},31,[114],"The goal of this clinical trial (Phase II) is to evaluate the efficacy and safety of neoadjuvant Adebrelimab combined with chemoradiation in patients with locally advanced thymic carcinoma. The main questions it aims to answer are:\n\n* Is neoadjuvant therapy with Adebrelimab plus chemoradiation effective?\n* Is this combination treatment safe and tolerable in this patient population?\n\nParticipants will:\n\n* Receive 2-4 cycles of neoadjuvant Adebrelimab combined with a platinum-based chemotherapy regimen (such as carboplatin plus paclitaxel) and concurrent radiotherapy prior to surgery.\n* Undergo re-staging imaging to assess tumor response and determine surgical candidacy.\n* Undergo surgical resection if the tumor is resectable after neoadjuvant treatment.\n* Receive adjuvant Adebrelimab therapy for up to one year following surgery.\n* Undergo regular follow-up visits for safety monitoring and survival assessment.",[455],"Thymic Carcinoma",[457,458,459,460,169],"thymic carcinoma","locally advanced","neoadjuvant","adebrelimab","2026-03-15",{"date":436,"type":44},{"date":224,"type":23},{"date":465,"type":23},"2030-03-01",{"name":50,"class":51},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":474,"targetDuration":4,"studyType":24,"phases":476,"briefSummary":477,"conditions":478,"keywords":479,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":488,"locationsCount":52},"100500637","phase-2-the-effect-of-toripalimab-plus-radiotherapy-in-patients-with-operable-stage-ii-iiia-n-non-small-cell-lung-cancer-100500637","NCT05798845","The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer","Exploratory Phase II Clinical Study of Toripalimab Plus Radiotherapy Versus Toripalimab Plus Chemotherapy for the Neoadjuvant Treatment of Operable Stage II-IIIA (N+) Non-small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Age 18 to 75 years old, gender is not limited.\n2. ECOG performance status 0-1.\n3. non-small cell lung cancer diagnosed by pathology.\n4. sufficient tumor tissue available for biomarker analysis.\n5. clinical staging of cT1-2N1-2M0 or T3N1M0, stage II-IIIA (8th UICC staging criteria).\n6. Patients with distant metastases ruled out by CT or PET\u002FCT and physically assessed as acceptable for radical lung cancer surgery.\n7. histomolecular pathology confirming the absence of classic driver oncogene mutations in EGFR, ALK, or ROS1.\n8. Basic normal function of all organs (laboratory test results within 1 week prior to enrollment).\n\n   * Bone marrow function: absolute neutrophil count (ANC) ≥ 1.5x109 \u002FL, platelet count ≥ 100x109 \u002FL, hemoglobin ≥ 9g\u002FdL.\n   * Liver: serum total bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 2.5 times the upper limit of normal.\n   * Kidney: blood creatinine level ≤ 1.5 times the upper limit of normal or creatinine clearance ≥ 60 ml\u002Fmin and urea nitrogen ≤ 200 mg\u002FL.\n   * Urine protein \\\u003C+, if urine protein + then total 24 hour protein must be \\\u003C500mg.\n   * Blood glucose: within normal range and\u002For with diabetic patients on treatment but with stable blood glucose control.\n   * Pulmonary function: baseline FEV1 of at least 2L; if baseline FEV1 \\\u003C 2L then FEV1 \\> 800ml is expected after surgery as assessed by a surgical specialist.\n   * Cardiac function: no myocardial infarction within 1 year; no unstable angina; no symptomatic severe arrhythmia; no cardiac insufficiency.\n9. Voluntarily participated in this study and signed the informed consent form by himself or his agent\n\nExclusion Criteria:\n\n1. Pathology suggestive of compound small cell lung cancer, etc.\n2. History of previous lobectomy, radiotherapy or chemotherapy.\n3. Those with concurrent second primary carcinoma and a history of previous malignancy of less than 5 years (except for completely cured cervical carcinoma in situ or basal cell or squamous epithelial cell skin cancer).\n4. Patients with any active autoimmune disease or a history of autoimmune disease (e.g., interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, etc.).\n5. Have an active infection requiring systemic treatment or a history of active tuberculosis.\n6. Known history of human immunodeficiency virus (HIV) or active chronic Hepatitis C or Hepatitis B virus infection or any uncontrolled active systemic infection requiring intravenous (iv) antimicrobial treatment.\n7. Those with known presence or coexistence of other uncontrollable diseases that are not amenable to surgical treatment\n8. Physical examination or clinical trial finds that, in the opinion of the investigator, may interfere with the results or place the patient at increased risk for treatment complications\n9. Prior interstitial lung disease, drug-induced interstitial disease or any clinically evident active interstitial lung disease with idiopathic pulmonary fibrosis on baseline CT scan; uncontrolled massive pleural or pericardial effusion\n10. Unstable systemic concomitant disease (active infection, moderate to severe chronic obstructive pulmonary disease, poorly controlled hypertensive disease, unstable angina pectoris, congestive heart failure, myocardial infarction occurring within 6 months, severe mental disorder requiring medication for control, liver, renal or other metabolic disease, neuropsychiatric pathology such as Alzheimer's disease)\n11. History of congenital or acquired immunodeficiency disorders or organ transplantation\n12. Received any of the following treatments:\n\n    * Prior radiotherapy, treatment with anti PD-1, anti PD-L1 or anti PD-L2 drugs, or other drugs that synergistically inhibit T-cell receptors such as CTLA-4, OX-40, CD137.\n    * Having received any investigational drug within 4 weeks\n    * Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or an interventional clinical study follow-up\n    * Persons who have received an antineoplastic vaccine or who have received a live vaccine within 4 weeks\n    * Have undergone major surgery or had severe trauma within 4 weeks",{"count":475,"type":23},124,[114],"This randomized phase II trial is to explore the clinical efficacy, safety and feasibility of neoadjuvant immunotherapy plus radiotherapy compared with neoadjuvant immunotherapy plus chemotherapy in operable stage II-IIIA (N+) non small cell lung cancer (NSCLC) and the optimal radiotherapy pattern.",[272],[480,481],"neoadjuvant immunotherapy","radiotherapy","2026-03-09",{"date":484,"type":44},"2026-03-11",{"date":486,"type":44},"2025-02-20",{"date":358,"type":23},{"name":50,"class":51},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":24,"phases":497,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":52},"100567063","phase-1-intrathecal-injection-pemetrexed-and-bevacizumab-in-patients-with-leptomeningeal-metastases-in-nsclc-100567063","NCT06663306","Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC","Efficacy and Safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* ECOG PS score 0-3. ECOG PS score 2 or 3 should be due to leptomeningeal metastases.\n* Patients with pathologically diagnosed non-small cell lung cancer with cerebrospinal fluid and\u002For MRI diagnosis of leptomeningeal metastasis(LM);\n* Unsatisfactory efficacy of LM,which defined as disease progression in LM,or LM-related neurological progression, while patients received standard systemic anti-tumor treatment;\n* Expected survival time ≥ 1 month;\n* The laboratory test results meet the following criteria:Hemoglobin ≥ 90 g\u002FL, neutrophil count ≥ 1.5 × 10\\^9\u002FL, platelet count ≥ 100 × 10\\^9\u002FL; Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN ; Creatinine≤ 2.0 × ULN,or Creatinine clearance rate (CrCl) ≥ 50 mL\u002Fmin;\n* Females of child-bearing potential agree to use contraception during the study period and for 6 months after the completion of the study; patients who have had a negative serum or urine pregnancy test within seven days prior to enrollment in the study and who are not breastfeeding; and males agreeing to use contraception during the study period and for 6 months after the completion of the study;\n* Understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Positive for human immunodeficiency virus (HIV) ;\n* History of allergy to pemetrexed or bevacizumab;\n* History of pemetrexed and\u002For bevacizumab intrathecal Injection;\n* Presence of contraindication of bevacizumab:\n\n  1. Uncontrolled hypertension(systolic pressure≥150mmHg，or diastolic pressure≥100mmHg；History of hypertensive crisis or hypertensive encephalopathy;\n  2. Urine protein≥2+,or 24-hour urine protein≥2g；\n  3. Unstable angina pectoris, symptomatic congestive heart failure,myocardial infarction within 6 months before enrollment, severe vascular disease, severe uncontrolled arrhythmia;\n  4. Major hemoptysis within the past 1 month; History of coagulation disorders;\n  5. Presence of serious non-healing wounds, ulcers, or bone fractures\n  6. Presence of abdominal fistula, gastrointestinal perforation, or gastrointestinal tract obstruction;\n  7. Presence of macrovascular invasion；\n  8. Some neurological disorders unrelated to tumors，such as intracranial infection,cerebral hemorrhage,cerebral infarction,encephalitis;\n* Brain\u002Fspinal cord radiation therapy within 1 week before enrollment;\n* Pregnant and lactating female;\n* Refuse to use contraception during the study period;\n* Individuals considered by the investigator to be unsuitable for enrollment.",{"count":266,"type":23},[498],"PHASE1","This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.",[501,502],"Lung Cancer (NSCLC)","Leptomeningeal Metastasis",[504,272,505],"Leptomeningeal Metastases","Intrathecal Injection","2026-02-26",{"date":379,"type":44},{"date":509,"type":44},"2024-12-09",{"date":511,"type":23},"2027-12-30",{"name":50,"class":51},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":520,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":535},"100620438","phase-2-surufatinib-combined-with-chemo-versus-surufatinib-in-the-treatment-of-pulmonary-neuroendocrine-tumors-100620438","NCT07357623","Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors","Surufatinib Plus Standard Chemotherapy Versus Surufatinib Monotherapy in Patients With Pulmonary Neuroendocrine Tumors: a Randomized, Controlled, Open-label Study","Inclusion Criteria:\n\n1. Have a full understanding of this study and voluntarily sign the informed consent form;\n2. 18-75 years old (including cut-off value), male or female;\n3. Patients must have at least one measurable lesion (RECIST 1.1);\n4. Histologically or cytologically confirmed pulmonary neuroendocrine tumor (typical or atypical carcinoid) \\[at least one neuroendocrine immunohistochemistry marker (CD56, CgA, Syn) definitively positive on the basis of morphological features of neuroendocrine tumors\\];\n5. Patients who have not received systemic therapy in the past (Note: neoadjuvant or adjuvant chemotherapy is allowed in the early stage, and if disease progression\u002Frecurrence occurs ≥ 6 months after the end of neoadjuvant\u002Fadjuvant last therapy, it can also be included);\n6. ECOG PS 0-1 (PS 0-2 for amputees);\n7. Expected survival ≥ 12 weeks;\n8. Blood test (without blood transfusion within 14 days) 1) Absolute neutrophil value ≥1.5×109\u002FL, platelet ≥ 100×109\u002FL, hemoglobin ≥9g\u002FdL; 2) Liver function tests (AST and ALT≤2.5×ULN, total bilirubin≤1.5×ULN; AST and ALT ≤5×ULN) if liver metastases are present; 3) Renal function (serum creatinine ≤1.5×ULN, creatinine clearance (CCr) ≥60ml\u002Fmin);\n9. Male or female patients of childbearing potential voluntarily use effective contraceptive methods, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. during the study and within 6 months of the last study medication. All female patients will be considered of childbearing potential unless the female patient is naturally postmenopausal, has undergone artificial menopause, or has undergone sterilization (e.g., hysterectomy, bilateral adnextomy, or radioactive ovarian irradiation, etc.).\n\nExclusion Criteria:\n\n1. Patients who have received surufatinib or other anti-angiogenic drugs in the past;\n2. Received approved or investigational systemic anti-tumor therapy within 4 weeks before enrollment, including: chemotherapy, any form of radiotherapy, biological immunotherapy, targeted therapy, etc.;\n3. Participated in other domestic drug clinical trials that have not been approved or marketed within 4 weeks before enrollment and received corresponding trial drug treatment;\n4. Undergoing any surgery or invasive treatment or operation within 4 weeks before enrollment that affects wound healing (except for intravenous catheterization, puncture and drainage, etc.);\n5. International normalized ratio (INR) \\> 1.5 or partially activated prothrombin time (APTT) \\>1.5× ULN;\n6. Clinically significant electrolyte abnormalities judged by the investigator;\n7. Presence of hypertension that cannot be controlled by medication, as prescribed as: systolic blood pressure ≥140 mmHg and\u002For diastolic blood pressure ≥90 mmHg;\n8. Patient currently has any disease or condition that affects drug absorption, or patient cannot take surufatinib orally;\n9. Patients currently have active gastric and duodenal ulcers, ulcerative colitis and other gastrointestinal diseases or unresected tumors with active bleeding, or other conditions that may cause gastrointestinal bleeding and perforation as determined by the investigator;\n10. Patients with obvious evidence or history of bleeding tendency within 3 months prior to enrollment (bleeding \\>30 mL within 3 months, hematemesis, black feces, blood in the stool), hemoptysis (\\>5 mL of fresh blood within 4 weeks), or thromboembolic events (including stroke events and\u002For transient ischemic attack) within 12 months;\n11. Significant clinically significant cardiovascular disease, including but not limited to the following: acute myocardial infarction, severe\u002Funstable angina, or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure New York Heart Association (NYHA) grade \\>2; ventricular arrhythmias requiring medication; LVEF (left ventricular ejection fraction) \\\u003C 50%;\n12. Other malignant tumors within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;\n13. Active or uncontrolled serious infection:\n\n1\\) Known human immunodeficiency virus (HIV) infection; 2) Known history of clinically significant liver disease, including viral hepatitis \\[known hepatitis B virus (HBV) carriers must rule out active HBV infection, i.e., HBV DNA positive (\\>1×104 copies\u002FmL or \\>2000 IU\u002Fml); 3) Known hepatitis C virus infection (HCV) with positive HCV RNA (\\>1×103 copies\u002FmL), or other hepatitis, cirrhosis; 14. Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Subjects who have been previously treated for brain metastases may be enrolled provided that the patient's disease is clinically stable for at least 2 weeks and there is no evidence of new or enlarging brain metastases and steroids are off 3 days prior to administration of study drug. According to this definition, stable brain metastases should be determined prior to the first dose of study drug. Subjects with asymptomatic brain metastases (i.e., no neurological symptoms, no need for corticosteroids, and no lesions \\>1.5 cm) may be enrolled, but require regular imaging of the brain as a site of disease; 15. Patients with persistent toxicity caused by any previous anti-tumor therapy that has not recovered to grade ≤2, but have any grade of alopecia and lymphopenia are allowed to participate in this study; 16. Pregnant (positive pregnancy test before medication) or breastfeeding; 17. Received blood transfusion therapy, blood products and hematopoietic factors such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment; 18. The investigator believes that the subject has any clinical or laboratory abnormalities or other reasons that are not suitable for participation in this clinical study; 19. Those who showed urine protein ≥ 2 and had a quantitative of \\> 1.0g in 24 hours;",{"count":521,"type":23},96,[114],"The goal of this clinical trial is to investigate if chemotherapy works with surufatinib to treat pulmonary neuroendocrine tumors. It will also learn about the safety of this combination regimen. The main questions it aims to answer are:\n\nDoes chemotherapy combined with surufatinib could bring more survival benefits (ie. higher response rate or longer survival time) for patients with pulmonary neuroendocrine tumors? Is this combination regimen safe?\n\nResearchers will compare chemotherapy plus surufatinib with surufatinib monotherapy to see if this combination regimen works to treat pulmonary neuroendocrine tumors.\n\nParticipants will:\n\nTake chemotherapy(Etoposide+Carboplatin, EC or Capecitabine+Temozolomide, CAPTEM) plus surufatinib or surufatinib monotherapy every 3 or 4 weeks as a cycle.\n\nVisit the clinic once every cycle for checkups and tests. Tumor assessment is performed every 2 cycles. Treatment will continued until disease progression, death, intolerable toxicity, or withdrawn.",[525],"Pulmonary Neuroendocrine Tumor",[527],"surufatinib, NET, Typical carcinoid, Atypical carcinoid","2026-01-20",{"date":530,"type":44},"2026-01-22",{"date":532,"type":44},"2025-09-22",{"date":74,"type":23},{"name":50,"class":51},4,{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":545,"briefSummary":546,"conditions":547,"keywords":551,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":561},"100514415","phase-2-radiotherapy-combined-with-immunochemotherapy-in-metastatic-esophageal-squamous-cell-carcinoma-100514415","NCT05978193","Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma","First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center Trial (SCR-ESCC-01)","SCR-ESCC-01","Inclusion Criteria:\n\n1. Age ≥18;\n2. Metastatic esophageal squamous cell carcinoma (stage IVB, M1) confirmed by pathology;\n3. ECOG performance status: 0-1 point;\n4. No prior anti-tumor treatment;\n5. Adequate hematologic, renal, hepatic, and cardiac functions that meet the requirements for chemotherapy and immunotherapy assessed by investigators.\n\nExclusion Criteria:\n\n1. Non-squamous cell esophageal carcinoma or ESCC mixed with other pathological types of esophageal cancer;\n2. Patients who are potentially curable with surgery as assessed by investigators;\n3. Pleural metastasis or malignant pleural effusion, pericardial effusion;\n4. Any prior anti-tumor therapy for esophageal cancer, i.e., surgery, radiotherapy, chemotherapy, or immunotherapy;\n5. High risk of gastrointestinal bleeding, esophageal fistula, or perforation;\n6. Patients with Patient-Generated Subjective Globe Assessment (PG-SGA) score≥9;\n7. Unstable cardiac diseases or symptoms;\n8. History of interstitial pulmonary disease, non-infectious pneumonitis; pulmonary fibrosis, or other uncontrolled acute pulmonary disease;\n9. Active autoimmune disease or history of autoimmune disease;\n10. Conditions of immunodeficiency or active infection requiring systemic therapy;\n11. Pregnant or breastfeeding;\n12. Patients with synchronous second primary cancer and a history of malignancy within the past 5 years (excluding completely cured cervical carcinoma in situ or basal cell or squamous cell skin carcinoma).",{"count":315,"type":23},[114],"SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.",[548,549,550],"Esophageal Squamous Cell Carcinoma","Esophageal Cancer","Metastatic Esophageal Squamous Cell Carcinoma",[216,552,553,554],"low-dose radiotherapy","Esophageal squamous cell carcinoma","Immunoradiotherapy",{"date":530,"type":44},{"date":557,"type":44},"2023-01-01",{"date":559,"type":23},"2028-01-01",{"name":50,"class":51},2,{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":52},"100603387","sleeve-lobectomy-following-neoadjuvant-therapy-in-nsclc-100603387","NCT07135856","Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC","Comparative Analysis of Minimally Invasive and Open Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC: A Multicenter Retrospective Evaluation of Surgical Outcomes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed NSCLC\n* Undergoing sleeve lobectomy with curative intent\n* Receipt of neoadjuvant therapy (chemotherapy, immunotherapy, target therapy, etc.)\n* Surgical approach: either minimally invasive (VATS or RATS) or open thoracotomy\n* Availability of complete perioperative and follow-up data (minimum 12-month follow-up or until death)\n* Signed informative consent\n\nExclusion Criteria:\n\n* Sublobar resections (e.g., segmentectomy) or pneumonectomy\n* Absence of neoadjuvant therapy\n* Purely diagnostic surgical procedures\n* Incomplete medical records or lost to follow-up\n* Metastatic (stage IV) disease at time of surgery",{"count":570,"type":23},400,"The goal of this observational, retrospective, multicenter cohort study is to evaluate the surgical and oncologic outcomes of sleeve lobectomy performed via minimally invasive (RATS\u002FVATS) or open thoracotomy approaches in patients with non-small cell lung cancer (NSCLC) who have undergone neoadjuvant therapy, including chemotherapy, immunotherapy, or combination regimens. The main questions this study aims to answer are:\n\n* Does minimally invasive sleeve lobectomy result in comparable or improved perioperative and postoperative outcomes compared to open thoracotomy following neoadjuvant treatment in NSCLC?\n* Does surgical approach influence oncologic endpoints such as margin status, lymph node dissection, recurrence-free survival, and overall survival? This research addresses a critical gap in the thoracic oncology field by evaluating the safety, complexity, and efficacy of advanced surgical techniques in the context of evolving multimodal therapy paradigm. Findings may inform clinical decision-making and optimize patient selection in an era of increasing use of neoadjuvant strategies for resectable NSCLC.",[90,573],"Neoadjuvant Therapy","2025-12-30",{"date":576,"type":44},"2025-12-31",{"date":578,"type":44},"2025-09-01",{"date":580,"type":23},"2026-12-01",{"name":50,"class":51},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":590,"targetDuration":4,"studyType":24,"phases":592,"briefSummary":593,"conditions":594,"keywords":596,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":52},"100618446","epicardial-adipose-tissue-targeted-dapagliflozin-for-reducing-electrical-remodeling-in-atrial-fibrillation-100618446","NCT07331727","Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation","Efficacy of Dapagliflozin on Catheter Ablation Outcomes in Persistent Atrial Fibrillation Patients With Increased Epicardial Adipose Tissue","EAT-DARE-AF","Inclusion Criteria:\n\n* Age 18-80 years;\n\nDiagnosis of persistent atrial fibrillation (continuous AF \\>7 days and ≤5 years);\n\nPlanned first-time catheter ablation for AF;\n\nNo class I indications for dapagliflozin, defined as:\n\nNo diabetes mellitus;\n\nNo history of heart failure (HFrEF, HFmrEF, or HFpEF);\n\nNo chronic kidney disease (eGFR ≥60 mL\u002Fmin\u002F1.73 m²);\n\nEvidence of increased epicardial adipose tissue on cardiac CT or cardiac MRI, defined according to pre-specified imaging thresholds;\n\nAbility to provide written informed consent.\n\nExclusion Criteria:\n\n* Duration of persistent AF \\>5 years;\n\nLeft atrial anteroposterior diameter \\>50 mm on transthoracic echocardiography;\n\nPrior AF catheter ablation or surgical ablation;\n\nCurrent or recent (within 3 months) use of any SGLT2 inhibitor;\n\nSevere structural heart disease (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy);\n\nContraindications to catheter ablation (e.g., left atrial thrombus, active infection);\n\nEstimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m²;\n\nType 1 diabetes or history of diabetic ketoacidosis;\n\nPregnancy or breastfeeding;\n\nAny condition deemed by investigators to make study participation inappropriate.",{"count":591,"type":23},280,[26],"Persistent atrial fibrillation (PeAF) is associated with a high risk of recurrence following catheter ablation despite advances in ablation technology and strategies. Beyond electrophysiological mechanisms, increasing evidence suggests that atrial structural and inflammatory remodeling plays a pivotal role in the initiation and maintenance of AF, particularly in persistent forms.\n\nEpicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and visceral pericardium. EAT shares a common microcirculation with the underlying atrial myocardium and exerts paracrine and vasocrine effects through the secretion of pro-inflammatory cytokines, adipokines, and profibrotic mediators. Increased EAT volume or thickness has been consistently associated with AF burden, atrial fibrosis, left atrial enlargement, and a higher risk of AF recurrence after catheter ablation.\n\nSodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated pleiotropic cardiovascular benefits beyond glucose lowering, including reduction in visceral adiposity, attenuation of systemic and local inflammation, and favorable effects on cardiac remodeling. Observational studies and randomized trials in patients with diabetes or heart failure suggest that SGLT2i therapy reduces incident AF and AF recurrence after ablation. However, the effect of SGLT2i in non-diabetic, non-heart failure patients-particularly those with increased EAT as a distinct pathophysiological substrate-remains unclear.This trial is designed to evaluate whether dapagliflozin, administered peri-ablation, can reduce atrial arrhythmia recurrence in PeAF patients with increased EAT but without class I indications for SGLT2i. This targeted approach aims to provide mechanistic and clinical evidence supporting metabolic-inflammatory modulation as an adjunctive strategy to catheter ablation.",[595],"Atrial Fibrillation (AF)",[597],"Atrial Fibrillation","2025-12-29",{"date":600,"type":44},"2026-01-12",{"date":602,"type":23},"2026-01-01",{"date":358,"type":23},{"name":50,"class":51},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":61,"enrollmentInfo":612,"targetDuration":4,"studyType":24,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":4},"100614562","phase-2-a-study-of-shr-a1811-combined-with-adebelimumab-as-neoadjuvant-therapy-for-resectable-her2-altered-non-small-cell-lung-cancer-100614562","NCT07281209","A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer","A Single-Arm Phase II Clinical Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Having sufficient understanding of this study and being willing to sign the informed consent form (ICF);\n2. Aged 18-75 years, male or female;\n3. Treatment-naive, histologically confirmed resectable, stage II, IIIA, IIIB (AJCC staging system, version 9) NSCLC\n4. HER2 alterations identified by histological specimens;\n5. Measurable lesions based on the response evaluation criteria in solid tumors version 1.1 (RECIST v1.1);\n6. ECOG score 0-1;\n7. No contraindications to immunotherapy;\n8. Adequate organ function:\n9. Being willing and able to comply with the visits, treatment plan, laboratory examinations and other study procedures scheduled in the study;\n10. Pulmonary function being able to withstand the planned surgery evaluated by surgeons;\n11. Women of childbearing potential must undergo a serum pregnancy test within 1 week prior to the first dose and the result must be negative. Female patients of childbearing potential and male subjects whose partners are women of childbearing potential must agree to use highly effective contraceptive methods during the study period and within 180 days after the last dose of study drug\n\nExclusion Criteria:\n\n1. Known EGFR sensitizing mutations or ALK fusions.\n2. Malignant pleural effusion. Drainable effusions during screening require thoracentesis to rule out malignancy.\n3. Prior anticancer therapy (radiotherapy, chemotherapy, immunotherapy), except curatively treated NSCLC with ≥5 years recurrence-free. Anticancer Chinese herbal medicine is allowed if stopped ≥2 weeks prior.\n4. Active or history of autoimmune diseases (e.g., uveitis, hepatitis, vasculitis, thyroiditis). Exceptions include: resolved childhood asthma, vitiligo, psoriasis, or alopecia without systemic treatment. Patients requiring bronchodilators are excluded.\n5. Immunodeficiency (e.g., HIV), active Hepatitis B (HBsAg+ \\& HBV DNA ≥500 IU\u002FmL), or active Hepatitis C (HCV Ab+ \\& detectable HCV RNA). Resolved HBV infection (anti-HBc+, HBsAg-) is allowed.\n6. Uncontrolled third-space fluid accumulation requiring repeated drainage.\n7. Significant proteinuria (urine protein ≥++ and 24-hour protein ≥1.0 g) or severe hepatic\u002Frenal impairment.\n8. Systemic corticosteroids (\\>10 mg\u002Fday prednisone equivalent) or immunosuppressants within 14 days prior to first dose. Inhaled\u002Ftopical steroids or physiologic replacement doses are permitted.\n9. Antitumor vaccines or immunostimulatory agents within 1 month prior to first dose.\n10. Systemic immunosuppressive therapy within 2 weeks prior to first dose or anticipated need during the study. Short-term, low-dose use may be permitted after Medical Monitor approval.\n11. Concurrent participation in another interventional clinical trial or prior interventional drug within 4 weeks (or 5 half-lives). Non-interventional study participation is allowed.\n12. Known or suspected interstitial lung disease, or other significant pulmonary conditions that may interfere with drug-related pulmonary toxicity evaluation.\n13. Severe cardiovascular disease, including: clinically significant arrhythmias; QTc ≥450 ms (male) or ≥470 ms (female); NYHA Class ≥III heart failure; or LVEF \\\u003C50%.\n14. Severe infection within 4 weeks prior to first dose, or active infection requiring therapeutic antibiotics within 2 weeks prior (prophylactic antibiotics allowed).\n15. Active tuberculosis within 1 year prior to first dose.\n16. Major surgery within 28 days prior to first dose.\n17. History of allogeneic organ or stem cell transplantation.\n18. Pregnancy, lactation, or unwillingness to use effective contraception.\n19. Known allergy or hypersensitivity to SHR-A1811\u002FAdebelimumab or their excipients.\n20. History of psychoactive drug abuse, alcohol abuse, or drug addiction. 21 Any other condition that may compromise patient safety or study compliance, per investigator's judgment.",{"count":613,"type":23},40,[114],"This is a prospective, single-arm, multi-center Phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant therapy with SHR-A1811 in combination with Adebelimumab in patients with resectable, early-stage non-small cell lung cancer (NSCLC) harboring HER2 alterations.",[272],"2025-12-01",{"date":619,"type":44},"2025-12-15",{"date":621,"type":23},"2025-12",{"date":201,"type":23},{"name":50,"class":51},""]